Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder

To see complete record on, please visit this link

Id: NCT05035927

Organisation Name: TRYP Therapeutics

Overal Status: Recruiting

Start Date: March 16, 2022

Last Update: May 4, 2022

Lead Sponsor: TRYP Therapeutics

Brief Summary: To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP 8802 among individuals with Binge Eating Disorder. This is a single-center phase 2a open-label study to assess the safety and feasibility of a single dose of TRP 8802 in subjects with BED. Subjects will undergo screening, preparation therapy sessions, dosing, integration therapy sessions, and follow-up for 12 weeks following the dose of TRP 8802. The total participation in the study will be up to approximately 5 months.

  • Binge Eating Disorder

Total execution time in seconds: 0.315584897995